Santarus Inc (SNTS)

[surf1944]

4:18AM Santarus and Pharming provides new data on treatment with the investigational drug RHUCIN; treatment response rates founded to be 90% or greater (SNTS) 3.29 : Co and Pharming announce new data on 62 patients with Hereditary Angioedema who received repeat treatment with the investigational drug RHUCIN for 168 acute angioedema attacks. The median time to beginning of relief of symptoms across treatments for repeat attacks was ~60 minutes with response rates that were consistently 90% or greater. Time to beginning of relief was assessed by patients using a 100 mm visual analog scale (VAS). Of the 168 attacks, 90% were treated with a single dose of 50 U/kg of RHUCIN. More than 90% of the attacks responded within four hours of treatment. In addition, there were no relapses of attacks following treatments. In the safety analysis of the adverse events, 39 (63%) of the patients reported at least one AE; most of the AEs were considered mild to moderate in severity and 7 patients experienced an AE that was considered severe. None of the AEs were considered to be probably or definitely related to the study drug. The overall incidence of AEs was similar to those in the placebo groups in previously conducted clinical studies with RHUCIN. The frequency of adverse events did not increase upon repeat administrations.